Saltar al contenido
Merck

PADI2-Mediated Citrullination Promotes Prostate Cancer Progression.

Cancer research (2017-08-19)
Lin Wang, Guanhua Song, Xiang Zhang, Tingting Feng, Jihong Pan, Weiwen Chen, Muyi Yang, Xinnuo Bai, Yu Pang, Jindan Yu, Jinxiang Han, Bo Han
RESUMEN

Onset of castration-resistance prostate cancer (CRPC) after long-term androgen deprivation therapy remains a major obstacle in the treatment of prostate cancer. The peptidylarginine deiminase PADI2 has been implicated in chronic inflammatory diseases and cancer. Here we show that

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
MISSION® esiRNA, targeting human PADI2